We are a drug discovery company passionate about using radical approaches to develop transformative treatments targeting G protein-coupled receptors (GPCRs.) While we recognize the importance of traditional assays, we believe the path to better therapeutics requires innovative technologies. 

Through our proprietary genetically encoded GPCR biosensors, our vision is to revolutionize GPCR drug discovery. 

Our discovery programs aim to bring forth first-in-class and best-in-class preclinical candidates in CNS indications targeting new and challenging GPCRs.

Co-Founder & CEO

Grace O. Mizuno, Ph.D.

Grace has 11 years of life science experience, is a business strategy consultant and is the hands on domain expert who developed the company’s platform technology. Grace is an award winning speaker, researcher and has published her work in Cell and Nature.


Lin Tian, Ph.D.

Lin is a leading expert in protein engineering. She engineered the first calcium biosensor (GCaMP3) sensitive for in vivo imaging. Through her inventions, Lin has revolutionized in vivo fluorescent imaging. She has received numerous awards such as the NIH Director’s Innovator Award, Rita Allen Young Scholar, Hartwell Foundation Individual Biomedical Research Award, Human Frontier Science Program Young Investigator Award, HHMI Research Fellowship just to name a few. 


ScientifiC advisor

Lin Tian, Ph.D.

Associate Professor, UC Davis

Scientific advisor

Mark Von Zastrow, M.D., Ph.D.

Professor, UCSF

Scientific advisor

Kit Lam, M.D., Ph.D.

Professor, UC Davis

Strategic advisor

Friedhelm Blobel, Ph.D.

Former CEO and  President of SciClone Pharmaceuticals